Sold as Soma Compound W/ Codeine. Every FDA application for this active ingredient: 1 branded and 3 generic. Boxed warning Withdrawn in European Union, Malaysia; Bangladesh
As of Nov 22, 2026, FDA lists 4 applications for Aspirin; Carisoprodol; Codeine phosphate (sold as Soma Compound W/ Codeine), first approved Oct 5, 1960, with 0 new uses approved and 0 published complete response letters.
| Oct 5, 1960 | Soma Compound W/ CodeineNDA 12366 · New combination | Meda Pharmaceuticals | 19 | Discontinued |
| Apr 16, 1996 | Carisoprodol, Aspirin and Codeine PhosphateANDA 40118 | Sandoz | 16 | Discontinued |
| Dec 29, 1998 | Carisoprodol, Aspirin and Codeine PhosphateANDA 40283 | Oxford Pharmaceuticals | 3 | Discontinued |
| Jan 7, 2010 | Carisoprodol, Aspirin and Codeine PhosphateANDA 40860 | Ingenus Pharms Nj | 14 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA